When applied responsibly, AI empowers medical, commercial, and access teams to make faster, evidence-based decisions and ...

This video captures the essence of a very special 10th Anniversary Frontiers Health - visionary talks, groundbreaking ...

Novo Nordisk said it will now move ahead with a phase 3 programme for both versions of the drug in adults with type 2 ...

Digital health is now an essential tool to scaling healthcare, but there are still many challenges to deploying it scalably ...

Reimbursement authority NICE has ruled that London-based Autolus' Aucatzyl (obecabtagene autoleucel or obe-cel) can be used ...

In a boost for the UK life sciences sector, a new life sciences hub located at Barts Health NHS Trust in London has opened ...

At Frontiers Health 2025, we spoke with Meri Beckwith (Lindus Health), Daniel Diezi (Gerresheimer), and David Benshoof Klein ...

Dual glucagon (GCG) and GLP-1 agonist mazdutide is already approved for both type 2 diabetes and obesity in China at doses ...

Graphite Digital’s study of 100 senior pharma leaders across Europe and North America earlier this year investigated ...

Phil Davey is the General Manager at Alnylam for the UK, Ireland, the Nordics, and Canada. With over 20 years in the ...

The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age, and could free them from having to take regular, lifelong SMA treatments ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...